Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058510 · ClinicalTrials.gov registry record
Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 30
- Enrollment target
NCT03058510: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03058510 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03058510 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
ORBID-OA is a single-center, observational study in 30 patients with stable coronary artery disease. The aim of the study is to analyze the outcomes of main vessel stenting on side branch in calcified bifurcation lesion and identify preprocedural predictors of side branch complication by utilizing two-dimensional (2D) and three-dimensional (3D) frequency domain optical coherence tomography (FD-OCT).
Primary Outcome
Incidence of placing a stent with less than 50% residual stenosis
Interventions
- PROCEDURE Frequency domain optical coherence tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-01-17 |
| Est. Completion | 2017-10-13 |
What the finished NCT03058510 record still lists
NCT03058510 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Frequency domain optical coherence tomography is the first listed.
NCT03058510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03058510 about?
NCT03058510 is a clinical study titled "Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion". ORBID-OA is a single-center, observational study in 30 patients with stable coronary artery disease. The aim of the study is to analyze the outcomes of main vessel stenting on side branch in calcified bifurcation lesion and identify preprocedural predictors of side branch complication by utilizing ...
What is the current status of trial NCT03058510?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2016-01-17. Estimated completion is 2017-10-13.
What interventions are being tested in trial NCT03058510?
The interventions under investigation include: Frequency domain optical coherence tomography (PROCEDURE).
Who is sponsoring clinical trial NCT03058510?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI